Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 12:45 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Infection Clear all
Completed Phase 1 Interventional

A Phase I/II Open-Labelled Trial of Intravitreal Ganciclovir Salvage Therapy for AIDS Patients With Active CMV Retinitis Who Are Intolerant of Systemic Therapy

NCT00000673
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Miami, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 3 Interventional

Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter

NCT00006083
View directory record Official record
Conditions
Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific, Veno-occlusive Disease
Interventions
Fragmin, placebo
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 2, 2026, 12:45 AM EST
Completed No phase listed Observational

Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

NCT02876341
View directory record Official record
Conditions
Atrial Fibrillation, Septic Shock
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 1Phase 2 Interventional

Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants

NCT01203488
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Respiration, Artificial, Respiratory Distress Syndrome, Newborn, Sepsis
Interventions
Vitamin A, Sham Procedure
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Hours
Enrollment
807 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Nov 2, 2026, 12:45 AM EST
Terminated Not applicable Interventional

The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis

NCT02130388
View directory record Official record
Conditions
Sepsis
Interventions
Zinc
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Nov 2, 2026, 12:45 AM EST
Terminated Phase 4 Interventional Results available

Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use

NCT05521880
View directory record Official record
Conditions
Substance Use Disorders, Infection, Soft Tissue, Bacteremia, Osteomyelitis Acute, Septic Arthritis
Interventions
Oritavancin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 2, 2026, 12:45 AM EST
Completed No phase listed Observational

HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs

NCT00007488
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
23
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 3 Interventional Results available

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

NCT02651428
View directory record Official record
Conditions
Kidney Failure, Chronic, Catheter-Related Infections
Interventions
Neutrolin, Heparin
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Nov 2, 2026, 12:45 AM EST
Withdrawn No phase listed Observational

Multi-marker INDex for the Risk Assessment of Sepsis in the Emergency departmenT (MINDSET)

NCT00472628
View directory record Official record
Conditions
Sepsis
Interventions
Blood samples collected
Procedure
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Nov 2, 2026, 12:45 AM EST
Terminated Phase 3 Interventional Results available

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

NCT00108433
View directory record Official record
Conditions
Bacteremia, Gram-Positive Bacterial Infections
Interventions
Cefazolin IV, Linezolid IV, Vancomycin (IV)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 2 Interventional Results available

HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients

NCT03710187
View directory record Official record
Conditions
Septic Shock
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Nov 2, 2026, 12:45 AM EST
Completed Not applicable Interventional Results available

Fluid Responsiveness Evaluation in Sepsis-associated Hypotension

NCT02837731
View directory record Official record
Conditions
Sepsis, Hypotension
Interventions
Treatment Starling SV monitor
Device
Lead sponsor
Cheetah Medical Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Nov 2, 2026, 12:45 AM EST
Completed No phase listed Observational

Quality of Life in Younger Leukemia and Lymphoma Survivors

NCT00956475
View directory record Official record
Conditions
Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions
telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Nov 2, 2026, 12:45 AM EST
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 2 Interventional Results available

Inulin for Infections in the Intensive Care Unit

NCT03865706
View directory record Official record
Conditions
Antibiotic Resistant Infection, Nosocomial Infection, Pathogen Transmission, Nutrition Disorders, Critical Illness, Sepsis
Interventions
Inulin Oral Suspension, Placebo Oral Suspension, Broad-spectrum antibiotics
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 2, 2026, 12:45 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases

NCT04690816
View directory record Official record
Conditions
Systemic Autoimmune Diseases
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
15 Years and older
Enrollment
293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 2, 2026, 12:45 AM EST
Terminated Not applicable Interventional Results available

Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury

NCT01400893
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
SCD
Device
Lead sponsor
SeaStar Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 1 Interventional Results available

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

NCT01393782
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II
Drug
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 1 Interventional

PS-341 in Treating Patients With Advanced Cancer

NCT00006362
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
2
States / cities
Rochester, Minnesota • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 1 Interventional

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

NCT04681105
View directory record Official record
Conditions
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
Interventions
Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 1Phase 2 Interventional Results available

Dipyridamole for Immune Activation in HIV

NCT02121756
View directory record Official record
Conditions
HIV Infection
Interventions
Dipyridamole, Placebo, then Dipyridamole
Drug
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

NCT04362137
View directory record Official record
Conditions
Cytokine Storm (Covid-19)
Interventions
Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
11
States / cities
Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Nov 2, 2026, 12:45 AM EST
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 2, 2026, 12:45 AM EST
Terminated Phase 3 Interventional Results available

Ethanol Locks for the Treatment of Central Venous Line Infections

NCT00680459
View directory record Official record
Conditions
Bloodstream Infection
Interventions
70% ethanol, heparin flush solution
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
6 Months to 23 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Nov 2, 2026, 12:45 AM EST